Healthcare Industry News:  Micrus Endovascular 

Devices Interventional FDA

 News Release - May 16, 2006

Micrus Endovascular Receives FDA Clearance for Courier Microcatheter

SAN JOSE, Calif.--(HSMN NewsFeed)--May 16, 2006--Micrus Endovascular Corporation (Nasdaq:MEND ) today announced receipt of U.S. Food and Drug Administration (FDA) clearance to market its Courier(TM) microcatheter line in the United States. This product line is currently marketed in the European Union, having received CE Mark clearance in March 2006. Micrus intends to begin selling this product in the U.S. through its domestic direct sales force immediately.

"This clearance comes on the heels of FDA clearance for our Watusi(TM) guidewire platform announced last week," said John Kilcoyne, Micrus Endovascular president and CEO. "The addition of the Courier and Watusi to our U.S. product offering enables us to address a greater percentage of the growing domestic embolic procedure market."

About Micrus Endovascular Corporation

Micrus Endovascular develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists and neurosurgeons primarily to treat cerebral aneurysms responsible for hemorrhagic stroke, a significant cause of death worldwide. The Micrus product line enables physicians to gain access to the brain in a minimally invasive manner through the vessels of the circulatory system. Micrus' proprietary, three-dimensional microcoils are unique in that they automatically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells accessory devices and products used in conjunction with its microcoils. For more information, visit

Forward-Looking Statements

Micrus, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the Company's dependence upon the increased adoption of embolic coiling as a procedure to treat cerebral aneurysms, the Company's limited operating history and history of significant operating losses, the Company's involvement in patent litigation with Boston Scientific Corporation, fluctuations in quarterly operating results, which are difficult to predict, the Company's dependence on developing new products or product enhancements, challenges associated with rapid growth, challenges associated with complying with applicable state, federal and international regulations related to sales of medical devices and governing our relationships with physicians and other consultants, the Company's ability to compete with large, well-established medical device manufacturers with significant resources, the Company's dependence on obtaining timely FDA as well as applicable international regulatory clearances and approvals for our future products or product enhancements, and other risks as detailed from time to time in the Company's final prospectus dated June 16, 2005 and reports and filings with the Securities and Exchange Commission under the Securities and Exchange Act of 1934. All forward-looking statements in this release represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update forward-looking statements.

Source: Micrus Endovascular

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.